Discovery of a novel metallo--lactamase inhibitor that potentiates meropenem activity against carbapenem-resistant enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 5, 2018, Pages

  Everett, Martin ^a   Sprynski, Nicolas ^a   Coelho, Alicia ^a   Castandet, Jérôme ^a   Bayet, Maëlle ^a   Bougnon, Juliette ^a   Lozano, Clarisse ^a   Davies, David T ^a   Leiris, Simon ^a   Zalacain, Magdalena ^a,b   Morrissey, Ian ^c   Magnet, Sophie ^c   Holden, Kirsty ^d   Warn, Peter ^d   De Luca, Filomena ^e   Docquier, Jean Denis ^e   Lemonniera, Marc ^a  

^a ANTABIO SAS   (France)

^b Zala Drug Discovery Consulting   (United States)

^c International Health Management Associates Europe Sàrl   (Switzerland)

^d Evotec   (United Kingdom)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

lactamase; Carbapenem; Inhibitor; Metallo lactamase; NDM 1; Resistance

Indexed keywords

ANT 431; ANTIBIOTIC AGENT; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; METALLO BETA LACTAMASE INHIBITOR; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CITROBACTER FREUNDII; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENTEROBACTER CLOACAE; ENZYME INHIBITION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HYDROLYSIS; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; THIGH; DRUG EFFECT; GENETICS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; MEROPENEM; MICROBIAL SENSITIVITY TESTS;

EID: 85046011862     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00074-18     Document Type: Article

References (38)

1. Miller CP, Bohnhoff M. 1945. Studies on the action of penicillin; development of penicilli resistance by gonococcus. Proc Soc Exp Biol Med 60:354–356. https://doi.org/10.3181/00379727-60-15187P.
2. Abraham EP, Chain E. 1940. An enzyme from bacteria able to destroy penicillin. Nature 146:837.
3. Hunter PA, Coleman K, Fisher J, Taylor D. 1980. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin. J Antimicrob Chemother 6:455–470. https://doi.org/10.1093/jac/6.4.455.
4. De Koning GA, Tio D, Coster JF, Coutinho RA, Ansink-Schipper MC. 1981. The combination of clavulanic acid and amoxycillin (Augmentin) in the treatment of patients infected with penicillinase producing gonococci. J Antimicrob Chemother 8:81–82.
5. Bush K, Jacoby GA, Medeiros AA. 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211–1233. https://doi.org/10.1128/AAC.39.6.1211.
6. Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jimenez-Martin MJ, Martinez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sanchez-Garcia M, Viale P, Wolff M, Carmeli Y. 2017. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 61:e01964-16. https://doi.org/10.1128/AAC.01964-16.
7. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. 2018. Evaluation of the in vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother 62:e01904-17. https://doi.org/10.1128/AAC.01904-17.
8. Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440–458. https://doi.org/10.1128/CMR.00001-07.
9. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrish-nan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597–602. https://doi.org/10.1016/S1473-3099(10)70143-2.
10. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046–5054. https://doi.org/10.1128/AAC .00774-09.
11. Li JJ, Munoz-Price LS, Spychala CN, DePascale D, Doi Y. 2016. New Delhi metallo-beta-lactamase-1-producing Klebsiella pneumoniae, Florida, USA. Emerg Infect Dis 22:744–746. https://doi.org/10.3201/eid2204.151176.
12. Savov E, Politi L, Spanakis N, Trifonova A, Kioseva E, Tsakris A. 6 September 2017. NDM-1 hazard in the Balkan States: evidence of the first outbreak of NDM-1-producing Klebsiella pneumoniae in Bulgaria. Mi-crob Drug Resist. https://doi.org/10.1089/mdr.2017.0230.
13. Haciseyitoglu D, Dokutan A, Abulaila A, Erdem F, Cag Y, Ozer S, Aktas Z. 2017. The first Enterobacter cloacae co-producing NDM and OXA-48 carbapenemases and interhospital spread of OXA-48 and NDM-producing Klebsiella pneumoniae in Turkey. Clin Lab 63:1213–1222. https://doi.org/10.7754/Clin.Lab.2017.170120.
14. Hussein NH. 1 September 2017. Emergence of NDM-1 among carbapenem-resistant Klebsiella pneumoniae in Iraqi hospitals. Acta Microbiol Immunol Hung https://doi.org/10.1556/030.64.2017.026.
15. Dong F, Lu J, Wang Y, Shi J, Zhen JH, Chu P, Zhen Y, Han SJ, Guo YL, Song WQ. 2017. A five-year surveillance of carbapenemase-producing Klebsiella pneumoniae in a pediatric hospital in China reveals increased predominance of NDM-1. Biomed Environ Sci 30:562–569.
16. Singh-Moodley A, Perovic O. 2016. Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa. BMC Infect Dis 16:536. https://doi.org/10.1186/s12879-016-1858-7.
17. Bocanegra-Ibarias P, Garza-Gonzalez E, Morfin-Otero R, Barrios H, Villarreal-Trevino L, Rodriguez-Noriega E, Garza-Ramos U, Petersen-Morfin S, Silva-Sanchez J. 2017. Molecular and microbiological report of a hospital outbreak of NDM-1-carrying Enterobacteriaceae in Mexico. PLoS One 12:e0179651. https://doi.org/10.1371/journal.pone.0179651.
18. Khan AU, Maryam L, Zarrilli R. 2017. Structure, genetics and worldwide spread of New Delhi metallo-beta-lactamase (NDM): a threat to public health. BMC Microbiol 17:101. https://doi.org/10.1186/s12866-017-1012-8.
19. Liu Z, Wang Y, Walsh TR, Liu D, Shen Z, Zhang R, Yin W, Yao H, Li J, Shen J. 2017. Plasmid-mediated novel blaNDM-17 gene encoding a carbapenemase with enhanced activity in a sequence type 48 Escherichia coli strain. Antimicrob Agents Chemother 61:e02233-16. https://doi.org/10 .1128/AAC.02233-16.
20. Dortet L, Poirel L, Nordmann P. 2014. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int 2014:249856. https://doi.org/10.1155/2014/249856.
21. Horsfall LE, Garau G, Lienard BM, Dideberg O, Schofield CJ, Frere JM, Galleni M. 2007. Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila. Antimicrob Agents Chemother 51:2136–2142. https://doi.org/10.1128/AAC.00866-06.
22. Pettinati I, Brem J, Lee SY, McHugh PJ, Schofield CJ. 2016. The chemical biology of human metallo-beta-lactamase fold proteins. Trends Biochem Sci 41:338 –355. https://doi.org/10.1016/j.tibs.2015.12.007.
23. Ordooei Javan A, Shokouhi S, Sahraei Z. 2015. A review on colistin nephrotoxicity. Eur J Clin Pharmacol 71:801–810. https://doi.org/10.1007/s00228-015-1865-4.
24. Dixit D, Madduri RP, Sharma R. 2014. The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti Infect Ther 12:397–400. https://doi.org/10.1586/14787210.2014.894882.
25. Choi JJ, McCarthy MW. 2018. Cefiderocol: a novel siderophore cephalo-sporin. Expert Opin Invest Drugs 27:193–197. https://doi.org/10.1080/13543784.2018.1426745.
26. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spell-berg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. 2017. Can ceftazidime-avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 61:e02243-16. https://doi.org/10.1128/AAC.02243-16.
27. Reck F, Bermingham A, Blais J, Capka V, Cariaga T, Casarez A, Colvin R, Dean CR, Fekete A, Gong W, Growcott E, Guo H, Jones AK, Li C, Li F, Lin X, Lindvall M, Lopez S, McKenney D, Metzger L, Moser HE, Prathapam R, Rasper D, Rudewicz P, Sethuraman V, Shen X, Shaul J, Simmons RL, Tashiro K, Tang D, Tjandra M, Turner N, Uehara T, Vitt C, Whitebread S, Yifru A, Zang X, Zhu Q. 2018. Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae—identification of LYS228. Bioorg Med Chem Lett 28:748–755. https://doi.org/10.1016/j.bmcl.2018.01.006.
28. Arjomandi OK, Hussein WM, Vella P, Yusof Y, Sidjabat HE, Schenk G, McGeary RP. 2016. Design, synthesis, and in vitro and biological evaluation of potent amino acid-derived thiol inhibitors of the metallo-beta-lactamase IMP-1. Eur J Med Chem 114:318–327. https://doi.org/10.1016/j.ejmech.2016.03.017.
29. Klingler FM, Wichelhaus TA, Frank D, Cuesta-Bernal J, El-Delik J, Muller HF, Sjuts H, Gottig S, Koenigs A, Pos KM, Pogoryelov D, Proschak E. 2015. Approved drugs containing thiols as inhibitors of metallo-beta-lactamases: strategy to combat multidrug-resistant bacteria. J Med Chem 58:3626–3630. https://doi.org/10.1021/jm501844d.
30. Yusof Y, Tan DT, Arjomandi OK, Schenk G, McGeary RP. 2016. Captopril analogues as metallo-beta-lactamase inhibitors. Bioorg Med Chem Lett 26:1589–1593. https://doi.org/10.1016/j.bmcl.2016.02.007.
31. Brem J, van Berkel SS, Aik W, Rydzik AM, Avison MB, Pettinati I, Umland KD, Kawamura A, Spencer J, Claridge TD, McDonough MA, Schofield CJ. 2014. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-beta-lactamase inhibition. Nat Chem 6:1084–1090. https://doi.org/10.1038/nchem.2110.
32. Liu XL, Yang KW, Zhang YJ, Ge Y, Xiang Y, Chang YN, Oelschlaeger P. 2016. Optimization of amino acid thioesters as inhibitors of metallo-beta-lactamase L1. Bioorg Med Chem Lett 26:4698–4701. https://doi.org/10.1016/j.bmcl.2016.08.048.
33. Brem J, Cain R, Cahill S, McDonough MA, Clifton IJ, Jimenez-Castellanos JC, Avison MB, Spencer J, Fishwick CW, Schofield CJ. 2016. Structural basis of metallo-beta-lactamase, serine-beta-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat Commun 7:12406. https://doi.org/10.1038/ncomms12406.
34. Yang SK, Kang JS, Oelschlaeger P, Yang KW. 2015. Azolylthioacetamide: a highly promising scaffold for the development of metallo-beta-lactamase inhibitors. ACS Med Chem Lett 6:455–460. https://doi.org/10.1021/ml500534c.
35. King AM, Reid-Yu SA, Wang W, King DT, De Pascale G, Strynadka NC, Walsh TR, Coombes BK, Wright GD. 2014. Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature 510: 503–506. https://doi.org/10.1038/nature13445.
36. Matsuura A, Okumura H, Asakura R, Ashizawa N, Takahashi M, Kobayashi F, Ashikawa N, Arai K. 1993. Pharmacological profiles of aspergilloma-rasmines as endothelin converting enzyme inhibitors. Jpn J Pharmacol 63:187–193. https://doi.org/10.1254/jjp.63.187.
37. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed. Approved standard M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
38. Docquier JD, Lamotte-Brasseur J, Galleni M, Amicosante G, Frere JM, Rossolini GM. 2003. On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother 51:257–266. https://doi.org/10.1093/jac/dkg067.